Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › B/F/TAF

B/F/TAF

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of B/F/TAF

17 trials tracked of B/F/TAF: 12 in phase 3 or 4 and 10 with published results. The most-cited published study has 394 citations.

17Trials tracked
12Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 2 Phase 3 10 Phase 2 2 Phase 1 3
  1. Phase 3 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Completed · 394 cited
  2. Phase 3 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Completed · 379 cited
  3. Phase 3 Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed Completed · 201 cited
  4. Phase 3 Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults Completed · 179 cited
  5. Phase 3 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed Completed · 112 cited
  6. Phase 3 Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults Completed · 59 cited
Show 11 more trials
  1. Phase 3 Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women Completed · 56 cited
  2. Phase 3 Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years Completed · 50 cited
  3. Phase 3 Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants Completed · 44 cited
  4. Phase 3 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis Completed · 33 cited
  5. Phase 4 B/F/TAF Switch Study for HIV-HBV Coinfection Completed
  6. Phase 4 Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) Completed
  7. Phase 2 Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV Completed
  8. Phase 2 Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed
  9. Phase 1 Study of Novel Antiretrovirals in Participants With HIV-1 Completed
  10. Phase 1 Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters Completed
  11. Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nomogram using baseline SUA and CD4+ count predicts hyperuricemia risk in people living with HIV
Diabetes & Endocrinology Cohort
Nomogram using baseline SUA and CD4+ count predicts hyperuricemia risk in people living with HIV What raises uric acid in HIV? New tool spots risk before symptoms start
This retrospective single-center study in Hangzhou, China derived and internally validated a nomogram predicting time to hyperuricemia (HUA)…
A new tool predicts high uric acid risk in HIV patients using just two factors: starting uric acid levels and CD4+ T-cell counts.
Frontiers Apr 16, 2026